|
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
2018
|
RCT |
29 |
↑Supports
|
A single ayahuasca dose produced significantly greater reductions in depression severity than placebo at all time points over seven days, with large between-group effect sizes. |
|
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
2015
|
observational |
|
↑Supports
|
Ayahuasca showed fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder. |
|
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
2016
|
systematic review |
|
↑Supports
|
Ayahuasca, psilocybin, and LSD may have beneficial effects for treatment-resistant depression, anxiety and depression associated with life-threatening diseases, and tobacco and alcohol dependence, but all reviewed studies had small sample sizes and many were open-label. |
|
Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
2001
|
single-blind crossover placebo-controlled clinical trial |
6 |
↑Supports
|
Ayahuasca produced significant dose-dependent psychological effects, was generally well tolerated, and induced changes of longer duration and milder intensity than intravenous DMT. |
|
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
2016
|
review |
|
↑Supports
|
Ayahuasca shows promise as a therapeutic tool by enhancing self-acceptance and allowing safe exposure to emotional events. |
|
Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members
2007
|
double-blind, placebo-controlled study |
|
↕Mixed
|
Under acute ayahuasca effects, participants scored lower on panic and hopelessness scales, but state- and trait-anxiety were not modified. |
|
Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies
2016
|
review |
|
↑Supports
|
Ayahuasca and its alkaloids warrant further investigation as potential treatments for anxiety and depression with fewer adverse effects. |
|
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers
2020
|
observational |
|
↑Supports
|
Ayahuasca enhances mindfulness and alters cognitive flexibility in the afterglow period, suggesting these as possible psychological mechanisms for its psychotherapeutic effects. |
|
A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats
2021
|
naturalistic observational study |
30 |
→No effect
|
Symptoms of depression, anxiety, and stress reduced in both ayahuasca and placebo groups over time, independent of treatment, though ayahuasca increased implicit emotional empathy to negative stimuli. |
|
Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder
2021
|
RCT |
17 |
↑Supports
|
Ayahuasca significantly improved self-perception of speech performance in socially anxious individuals, independent of task-related anxiety and emotion recognition. |
|
Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being
2021
|
naturalistic observational study |
43 |
↑Supports
|
A single ayahuasca ceremony was associated with increased cognitive empathy, satisfaction with life, and decentering, and decreased neuroticism and divergent thinking, lasting up to one week. |
|
Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.
2022
|
cross-sectional survey |
2510 |
↑Supports
|
Psychedelic use was associated with significant improvements in depressive and anxious symptoms and increased emotional well-being, with greater use linked to larger benefits up to a ceiling, but 13% of participants reported at least one harm from use. |
|
Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study
2021
|
prospective naturalistic study |
63 |
↑Supports
|
Participation in ayahuasca ceremonies was associated with statistically significant and sustained improvements in depression, anxiety, and psychological distress, and increased self-compassion. |
|
Therapeutic potential of ayahuasca in grief: a prospective, observational study
2020
|
observational cohort |
50 |
↑Supports
|
Ayahuasca ceremony participation was associated with large, sustained reductions in grief severity over 12 months, mediated by decreases in experiential avoidance and increases in decentering. |
|
Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers
2021
|
cross-sectional survey |
2011 |
↑Supports
|
78% of participants with depression and 70% with anxiety reported substantial improvement in their symptoms after consuming ayahuasca, while 2.7% and 4.5% reported worsening of depression or anxiety, respectively. |
|
Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats.
2026
|
preclinical animal study |
|
↑Supports
|
A single dose of ayahuasca attenuated maternal deprivation-induced anxiety- and depressive-like behaviors and neurochemical changes when assessed 15 days later. |
|
Effects of an international ceremonial ayahuasca retreat on the diversity and community composition of the human gut microbiome: A preliminary observational single-arm pre-post study
2026
|
observational single-arm pre-post study |
22 |
↑Supports
|
Participation in an ayahuasca retreat was associated with reduced PTSD symptoms, shifts in gut microbiome community composition, and increased relative abundances of several short-chain fatty acid-producing bacteria. |
|
Single exposure to Ayahuasca reverses chronic stress effects on sociability, anxiety, cortisol, and BDNF in zebrafish
2026
|
experimental study |
|
↑Supports
|
A single exposure to ayahuasca restored chronic stress-induced impairments in sociability, anxiety-like behavior, cortisol levels, and brain-derived neurotrophic factor in zebrafish. |
|
Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users
2026
|
cross-sectional study |
219 |
→No effect
|
Chronic ayahuasca use was not associated with detectable lasting neuropsychological impairments, and ayahuasca users showed no current psychopathological symptoms despite a higher lifetime prevalence of mood and anxiety disorders. |
|
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
2026
|
systematic review |
18 |
↕Mixed
|
Long-term changes were noted in wellbeing, depression, psychiatric symptoms, substance misuse, cognitive flexibility, personality, and prosocial behavior, but some participants experienced persisting psychiatric complications. |
|
The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.
2026
|
longitudinal observational study |
280 |
↑Supports
|
Ayahuasca combined with psychotherapeutic support was associated with significant reductions in depressive symptoms sustained for up to 180 days, though individual responses varied. |
|
Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings
2025
|
observational cohort |
58 |
↑Supports
|
Psilocybin and ayahuasca retreats significantly improved veterans' mental health and community reintegration, with the greatest improvements in depression and PTSD, and larger benefits for those with more severe initial symptoms. |
|
Ayahuasca Pretreatment Prevents Sepsis-Induced Anxiety-Like Behavior, Neuroinflammation, and Oxidative Stress, and Increases Brain-Derived Neurotrophic Factor.
2025
|
animal study |
|
↑Supports
|
Ayahuasca pretreatment prevented sepsis-induced anxiety-like behavior, increased anti-inflammatory interleukin-4 levels, and reduced oxidative stress in the brain. |
|
Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.
2025
|
prospective cohort study |
66 |
↑Supports
|
Ayahuasca use was associated with persisting improvements in mental health and wellbeing up to 12 months, with the largest symptom reductions in individuals diagnosed with depressive or anxiety disorders. |
|
Effects of ayahuasca on fear and anxiety: cross-talk between 5HT1A and 5HT2A receptors
2024
|
review |
|
↑Supports
|
Ayahuasca modulates neural substrates relevant for emotional processing, especially in serotonergic receptor-rich regions, and has specific effects on fear-related memories. |